-
Product Insights
Net Present Value Model: Movantik
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Movantik Drug Details Naloxegol oxalate (Movantik, Moventig,...
-
Product Insights
Net Present Value Model: Moventig
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Moventig Drug Details Naloxegol oxalate (Movantik, Moventig,...
-
Product Insights
Net Present Value Model: Resolor
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Resolor Drug Details Prucalopride succinate (Resolor)...
-
Product Insights
Net Present Value Model: Relistor
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Relistor Drug Details Methylnaltrexone bromide (Relistor)...
-
Product Insights
Net Present Value Model: Linzess
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Linzess Drug Details Linaclotide (Linzess, Constella,...
-
Product Insights
Net Present Value Model: Linzess/Constella
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Linzess/Constella Drug Details Linaclotide (Linzess, Constella,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BLI-801
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BLI-801 Drug Details BLI-801 was under development for the treatment of non-idiopathic constipation in...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – prucalopride succinate
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry prucalopride succinate Drug Details Prucalopride succinate (Resolor) is a dihydrobenzofuran-carboxamide derivative with enterokinetic properties....
-
Sector Analysis
Australian Consumer Credit 2019: Review, Forecasts, and Future Opportunities
The Australian consumer credit market has been characterized by continued weakness as consumers prioritize mortgage debt over consumer debt. The growth of the Australian mortgage market combined with high debt servicing costs has displaced the consumer credit market as a less competitive form of finance. Balances outstanding for both personal loans and credit cards are not expected to grow until 2021, with COVID-19 expected to significantly disrupt the economy and change buying habits. This report provides information and insight on...